Press Releases

Date Title
2/28/23 Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments
2/28/23 Sarepta Therapeutics Announces Call for Applications for the 6th Annual Route 79, The Duchenne Scholarship Program
2/28/23 Sarepta Therapeutics anuncia convocatoria de solicitudes para el 6.º Route 79 anual, el programa de becas Duchenne
2/21/23 Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results
2/17/23 Sarepta Therapeutics Announces Initiation of VOYAGENE, a Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
1/31/23 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/9/23 Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2022 Net Product Revenues
1/5/23 Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate
1/3/23 Sarepta Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
12/30/22 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Displaying 11 - 20 of 776